1) Amgen 
Romosozumab (AMG 785) is a humanized monoclonal antibody that targets sclerostin for the treatment of osteoporosis. Romosozumab was originally discovered by Celltech (now owned by UCB). Celltech entered in a partnership with Amgen in 2002 for the product`s development. Romosozumab is of interest because of sclerostin`s specificity to bone. Its u.....